Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail
IR@CDRI: CSIR-Central Drug Research Institute, Lucknow
View Archive InfoField | Value | |
Creator |
Valecha, Neena
Adak, T Bagga, A K Asthana, O P Srivastava, J S Joshi, Hema Sharma, V P |
|
Date |
2009-09-08T09:02:25Z
2009-09-08T09:02:25Z 2001 |
|
Identifier |
Current Science-2001, 80, 561-563
http://hdl.handle.net/123456789/508 |
|
Description |
One year follow-up of malaria patients was under-taken to minitor the antirelapse efficacy of CDRI compound 80/53 (Bulaquine).a total of 697 patients of plasmodium vivax malaria were included in three arm double blind randomized study comparing CDRI 80/53 with placebo and primaquine. Drugs were givan once a day for 5 days and the dose for CDRI 80/53 and primaquine was 25 mg and 15 mg, respectively. Thirty-four patients were lost to follow-up and 663 patients completed one year trail. Two hundred and fourteen patients came back with second episode during the one-year followup period. A detailed analysis revealed that the relapse rate during non-transmission period with placebo in 16 (10.6%) patients was higher than both in primaquine (3.0%) and CDRI 80/53 (4.9%) groups.
|
|
Format |
33746 bytes
application/pdf |
|
Language |
en
|
|
Title |
Comparative antirelapse efficacy of CDRI compound 80/53 (Bulaquine) vs primaquine in double blind clinical trail
|
|
Type |
Article
|
|